| Size | Price | Stock | Qty |
|---|---|---|---|
| 1g |
|
||
| 2g |
|
||
| 5g |
|
||
| Other Sizes |
| Targets |
Intermediate for the synthesis of Losartan impurities
Trityllosartan is an intermediate in the synthesis of losartan, which is an angiotensin II receptor blocker (ARB). Losartan itself targets the angiotensin II type 1 (AT1) receptor, blocking the action of angiotensin II and leading to vasodilation and reduced blood pressure. Trityllosartan does not have direct pharmacological activity as it is a protected intermediate. The trityl group is a protecting group that is removed in a later step of the synthesis to yield losartan. |
|---|---|
| ln Vitro |
In vitro, trityllosartan is not typically studied for biological activity, as it is an intermediate rather than a drug. Its role is in chemical synthesis rather than pharmacological assays. However, it can be used as a reference standard in analytical chemistry to identify and quantify impurities in losartan drug substance or drug products.
|
| ln Vivo |
In vivo, trityllosartan is not used as a therapeutic agent, so its in vivo activity is not relevant. It is a synthetic intermediate that is converted to losartan, which is then used therapeutically. The compound is not administered to patients.
|
| Enzyme Assay |
In vitro enzyme or receptor binding (non-cell) assays are not applicable for trityllosartan, as it is not a drug substance. However, it can be used as a reference standard in analytical methods, such as high-performance liquid chromatography (HPLC), to identify and quantify losartan impurities. Its chemical purity and identity are confirmed using techniques such as nuclear magnetic resonance (NMR) spectroscopy and mass spectrometry.
|
| Cell Assay |
In vitro cell-based assays are not applicable for trityllosartan, as it is not a drug substance. Its use is limited to chemical synthesis and analytical chemistry. It is not tested in cell-based assays for biological activity.
|
| Animal Protocol |
In vivo animal experiments are not applicable for trityllosartan, as it is not a therapeutic agent. It is not administered to animals for pharmacological or toxicological studies. Its use is limited to the production of losartan.
|
| ADME/Pharmacokinetics |
Pharmacokinetic (PK) properties are not applicable for trityllosartan, as it is not a drug substance. It is a synthetic intermediate that is not administered to patients. Its physicochemical properties, such as molecular weight and solubility, are relevant for its use in chemical synthesis. The compound has a molecular weight of 665.23 and a molecular formula of C41H37ClN6O. Powder is stable when stored at -20°C for 3 years; in solvent, it can be stored at -80°C for 1 year.
|
| Toxicity/Toxicokinetics |
Toxicology (toxicology) data are not relevant for trityllosartan as a drug substance, as it is not administered to patients. However, as a chemical intermediate, it should be handled with appropriate safety precautions. It may be irritant or harmful if ingested, inhaled, or absorbed through the skin. Standard laboratory safety practices should be followed when handling this compound.
|
| Additional Infomation |
Other information: Trityllosartan is a key intermediate in the synthesis of losartan, an angiotensin II receptor blocker used for the treatment of hypertension. It is also known as N-Trityllosartan or Losartan EP Impurity H. The compound is used as a reference standard for impurity testing in losartan drug substance and drug products. Its CAS number is 133909-99-6.
|
| Molecular Formula |
C41H37CLN6O
|
|---|---|
| Molecular Weight |
665.23
|
| Exact Mass |
664.271
|
| Elemental Analysis |
C, 74.03; H, 5.61; Cl, 5.33; N, 12.63; O, 2.41
|
| CAS # |
133909-99-6
|
| PubChem CID |
10865273
|
| Appearance |
Typically exists as solid at room temperature
|
| Density |
1.2±0.1 g/cm3
|
| Boiling Point |
856.6±75.0 °C at 760 mmHg
|
| Flash Point |
471.9±37.1 °C
|
| Vapour Pressure |
0.0±0.3 mmHg at 25°C
|
| Index of Refraction |
1.656
|
| LogP |
8.7
|
| Hydrogen Bond Donor Count |
1
|
| Hydrogen Bond Acceptor Count |
5
|
| Rotatable Bond Count |
12
|
| Heavy Atom Count |
49
|
| Complexity |
932
|
| Defined Atom Stereocenter Count |
0
|
| SMILES |
CCCCC1=NC(=C(CO)N1CC2=CC=C(C=C2)C3=CC=CC=C3C4=NN(C(C5=CC=CC=C5)(C6=CC=CC=C6)C7=CC=CC=C7)N=N4)Cl
|
| InChi Key |
QQPGGBNMTNDKEY-UHFFFAOYSA-N
|
| InChi Code |
InChI=1S/C41H37ClN6O/c1-2-3-23-38-43-39(42)37(29-49)47(38)28-30-24-26-31(27-25-30)35-21-13-14-22-36(35)40-44-46-48(45-40)41(32-15-7-4-8-16-32,33-17-9-5-10-18-33)34-19-11-6-12-20-34/h4-22,24-27,49H,2-3,23,28-29H2,1H3
|
| Chemical Name |
[2-butyl-5-chloro-3-[[4-[2-(2-trityltetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol
|
| Synonyms |
N2-Trityllosartan; N-Trityllosartan; Trityllosartan; 133909-99-6; Trityl losartan; N-Trityl Losartan; (2-Butyl-4-chloro-1-((2'-(2-trityl-2H-tetrazol-5-yl)-[1,1'-biphenyl]-4-yl)methyl)-1H-imidazol-5-yl)methanol; N-Trityllosartan; N2-Trityllosartan; [2-butyl-5-chloro-3-[[4-[2-(2-trityltetrazol-5-yl)phenyl]phenyl]methyl]imidazol-4-yl]methanol; Trityllosartan
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 1.5032 mL | 7.5162 mL | 15.0324 mL | |
| 5 mM | 0.3006 mL | 1.5032 mL | 3.0065 mL | |
| 10 mM | 0.1503 mL | 0.7516 mL | 1.5032 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
